Gemcitabine with the standard dose (1000 mg/m2) is equal to low dose (250 mg/m2) with just prolongation of the infusion time in Patients with Advanced Pancreatic cancer
- Conditions
- Cancer
- Registration Number
- PACTR201901862142418
- Lead Sponsor
- South Egypt cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Patients with advanced pancreatic cancer in males or females with age of 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, chemotherapy-naïve, and adequate hematologic, hepatic, and renal functions.
1.Patient refuses to be enrolled in study.
2.Contraindication to gemcitabine
3.Concurrent anticancer or radiation therapy.
?Start of study therapy must be at 4 weeks after completion of previous anticancer therapy and 2 weeks from the date of last radiation.
4.Use of gemcitabine within the past 3 months with progression.
5.Any psychiatric illness/social situations that would limit compliance with study requirements.
6.Pregnant or nursing women.
7.Synchronous malignancies i.e associated other body cancers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method